UK markets closed

Novartis AG (NOT.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
80.16+11.66 (+17.02%)
At close: 06:57PM CET
Full screen
Previous close80.16
Open0.00
Bid80.11 x 30000
Ask80.34 x 30000
Day's range0.00 - 0.00
52-week range
Volume1,589
Avg. volume0
Market cap179.196B
Beta (5Y monthly)N/A
PE ratio (TTM)8.30
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

    Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected between Q2-Q4 2024 Initiation of pivotal SEACRAFT-2 in NRASm melanoma expected in H1 2024 SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients wi

  • GlobeNewswire

    Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

    Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomasPelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement with a well-tolerated safety profile in Phase 3 MANIFEST-2 study, when administered in combination with ruxolitinib in JAK inhibitor-naive MF patients1 Pelabresib and ruxoliti

  • Yahoo Finance Video

    Novartis CEO explains 'prudent' 2024 guidance

    Novartis (NVS) reported fourth quarter results that missed analyst estimates. Novartis CEO Vas Narasimhan joins Yahoo Finance Live to discuss the company’s outlook for 2024 and plans for beyond. The company forecast mid-single digit percentage net sales growth, an estimate Narasimhan describes as “prudent.” Narasimhan says that though there will be headwinds due to the loss of exclusivity of some of its drugs, he overall believes the company has "the growth drivers to grow over the years to come.” Regarding recent supply issues with the company’s prostate cancer drug Pluvicto, Narasimhan insists that it's “one of the important growth drivers,” for the company and expects that with new manufacturing outlets, there will be “unconstrained supply.” Narasimhan acknowledges the competition in the oncology treatment sector, but says Novartis focuses on where it has “unique science and unique capabilities” such as Radioligand therapy and hematology. Watch the video above to hear what Narasimhan has to say about how the Inflation Reduction Act could harm drug development in the US. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Eyek Ntekim